Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of balcinrenone + dapagliflozin versus dapagliflozin in heart failure with renal impairment
CTR20243265Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of balcinrenone, dapagliflozin in heart failure (HF), sponsored by AstraZeneca. Started Nov 2024; status: active.
02
Drugs
balcinrenonedapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on CTR20243265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243265.